Ajt-Pharm-Antibacterial Indications

Front 1

penicillin

Back 1

g+, strep, listeria. Syphilis DOC

Front 2

ampicillin

Back 2

IV; g+ AND g-, proteus; ecoli, salmonella, shigella, h. flu spp; enterococcus + listeria DOC

Front 3

amoxicillin

Back 3

PO; g+ AND g-, proteus; ecoli, salmonella, shigella, h. flu spp; enterococcus + listeria DOC

Front 4

nafcillin

Back 4

IV; staph & strep (penicillinase resistant)

Front 5

piperacillin

Back 5

pseudomonas; combined w/ AGS/FQL; very wide spectrum w tazobactam

Front 6

augmentin

Back 6

amoxicillin + clavulanic acid

Front 7

cefazolin

Back 7

IV; staph & strep but not MRSA; surgical prophylaxis; cellulitis

Front 8

cephalexin

Back 8

PO; staph & strep but not MRSA; surgical prophylaxis; cellulitis

Front 9

cefoxitin

Back 9

IV; PID, lung abscesses, surgical prophylaxis (more g- at expense of g+)

Front 10

ceftriaxone

Back 10

IV; broad g-; lyme, meningitis, sepsis, gonorrhea

Front 11

ceftazidime

Back 11

IV; broad g-; pseudomonas, meningitis, sepsis

Front 12

imipenem

Back 12

empiric coverage of virtually all bacteria! NOT MRSA or VRE.

Front 13

meropenem

Back 13

like imipenem w/o seizures and renal degradation

Front 14

aztreonam

Back 14

IV/IM; GNRs; aerobes only. For resistant infxn or allergic/renal insufficient pts

Front 15

vancomycin

Back 15

IV or PO for pseudomembranous colitis; all G+ but reserved for resistant strains

Front 16

cycloserine

Back 16

2nd line anti TB drug

Front 17

bacitracin

Back 17

cell wall inhibitor for topical use; too toxic for systemic

Front 18

streptomycin

Back 18

ototoxic aminoglycoside; but useful vs. MDR M. tuberculosis

Front 19

gentamycin

Back 19

IV; tx of serious G- infections; synergy w/ B-lactams/vancomycin vs serious G+

Front 20

neomycin

Back 20

PO; poor GI absorption - topical antimicrobial for bowel surgery

Front 21

amikacin

Back 21

IV; AGS more potent vs psudomonas and resistant to inactivation than gentamycin

Front 22

tetracycline

Back 22

PO, IV; less potent; rx for acne

Front 23

doxycycline

Back 23

PO; IV; formerly broad spectrum; chlamydia, actinomyces, VRE

Front 24

minocycline

Back 24

PO, IV; widest spec TC, acne & lyme; more CNS effects, reversible vestibular toxicity

Front 25

tigecycline

Back 25

IV only; new TC class; many resistant G+ and G- strains.

Front 26

chloramphenicol

Back 26

PO; IV; possible DOC for meningitis (meningococcal, pneumococcal, H. flu) in B-lactam intolerant pts; topical eye infxns

Front 27

erythromycin

Back 27

PO; IV; CAP particulalry mycoplasma and legionella; chlamydia; DOC vs diptheria

Front 28

clarithromycin

Back 28

PO; IV; 2nd gen macrolide w greater activity vs G+C

Front 29

azithromycin

Back 29

PO, IV; extended spectrum macrolide w long T1/2 (3d)

Front 30

clindamycin

Back 30

PO, IV; anaerobic infxns above the diaphragm, G+C

Front 31

telithromycin

Back 31

ketolide, extended spectrum vs TC

Front 32

linezolide

Back 32

50S inhibitor; last resort vs MRSA and VRE

Front 33

metronidazole

Back 33

anaerobic infxns below diaphragm; superior coverage of G- anaerobes esp bacteroides

Front 34

daptomycin

Back 34

distinct mechanism; useful for multiple resistant G+ organisms

Front 35

sulfisoxazole

Back 35

PO; simple UTIs

Front 36

sulfamethoxazole

Back 36

in combo with trimethoprim for complicated UTIs

Front 37

clotrimazole

Back 37

yeast

Front 38

dapsone

Back 38

leprosy (with rifampin)

Front 39

ciprofloxacin

Back 39

wide range vs G-; UTIs, gastroenteritis, bronchitis

Front 40

nitrofurantoin

Back 40

bacteriostatic urinary antiseptic for acidic urine; chronic UTIs

Front 41

methenamine

Back 41

G- UTIs, NOT proteus; works via formaldehyde @ low pH